When we repeated the analysis adjusting for APOE ε4 dosage, the AD risk association of rs11665676 in MAPT H2 non‐carriers was abolished (APOE‐unadjusted OR = 0.7 and P = 1.33E‐07; APOE‐adjusted OR = 0.93 and P = 0.28), which is not surprising given the strong linkage disequilibrium (LD) of this variant with those that define APOE ε2/ε3/ε4 (rs429358 and rs7412). This evidence concerns the gene APOE and Alzheimer disease.